Dacomitinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dacomitinib
Dacomitinib.svg
Names
IUPAC name
(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
Other names
PF-00299804
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
KEGG
UNII
Properties
C24H25ClFN5O2
Molar mass 469.95 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Dacomitinib (PF-00299804) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1]

Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals.[2][3][4] Additional Phase III trials are ongoing.[2]

In 2017 results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[5]

As of August 2018, Pfizer has filed drug applications with the US FDA and the European Medicines Agency.[6]


References[edit]

  1. ^ "Dacomitinib". NCI Drug Dictionary. 
  2. ^ a b Zosia Chustecka (January 27, 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape. 
  3. ^ "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com. 28 January 2014. 
  4. ^ "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. January 27, 2014. 
  5. ^ Dacomitinib Sets PFS Record in Phase III NSCLC Trial. June 2017
  6. ^ H. Spreitzer (13 August 2018). "Neue Wirkstoffe - Dacomitinib". Österreichische Apothekerzeitung (in German) (17/2018). 

External links[edit]